Changzhou Qianhong Biopharma Co Ltd (002550) - Net Assets
Based on the latest financial reports, Changzhou Qianhong Biopharma Co Ltd (002550) has net assets worth CN¥2.76 Billion CNY (≈ $403.82 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.02 Billion ≈ $441.26 Million USD) and total liabilities (CN¥255.86 Million ≈ $37.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002550 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.76 Billion |
| % of Total Assets | 91.52% |
| Annual Growth Rate | 15.68% |
| 5-Year Change | 21.84% |
| 10-Year Change | 9.68% |
| Growth Volatility | 76.92 |
Changzhou Qianhong Biopharma Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Changzhou Qianhong Biopharma Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Changzhou Qianhong Biopharma Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Changzhou Qianhong Biopharma Co Ltd (2007–2024)
The table below shows the annual net assets of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2024. For live valuation and market cap data, see Changzhou Qianhong Biopharma Co Ltd (002550) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.52 Billion ≈ $368.25 Million |
+1.72% |
| 2023-12-31 | CN¥2.47 Billion ≈ $362.01 Million |
+1.66% |
| 2022-12-31 | CN¥2.43 Billion ≈ $356.08 Million |
+14.88% |
| 2021-12-31 | CN¥2.12 Billion ≈ $309.95 Million |
+2.55% |
| 2020-12-31 | CN¥2.07 Billion ≈ $302.24 Million |
-11.46% |
| 2019-12-31 | CN¥2.33 Billion ≈ $341.34 Million |
-8.10% |
| 2018-12-31 | CN¥2.54 Billion ≈ $371.42 Million |
+3.48% |
| 2017-12-31 | CN¥2.45 Billion ≈ $358.94 Million |
+1.17% |
| 2016-12-31 | CN¥2.42 Billion ≈ $354.79 Million |
+5.67% |
| 2015-12-31 | CN¥2.29 Billion ≈ $335.75 Million |
+7.59% |
| 2014-12-31 | CN¥2.13 Billion ≈ $312.08 Million |
+8.23% |
| 2013-12-31 | CN¥1.97 Billion ≈ $288.35 Million |
+5.44% |
| 2012-12-31 | CN¥1.87 Billion ≈ $273.47 Million |
+5.82% |
| 2011-12-31 | CN¥1.77 Billion ≈ $258.44 Million |
+326.83% |
| 2010-12-31 | CN¥413.78 Million ≈ $60.55 Million |
+69.80% |
| 2009-12-31 | CN¥243.68 Million ≈ $35.66 Million |
+11.79% |
| 2008-12-31 | CN¥217.99 Million ≈ $31.90 Million |
+3.01% |
| 2007-12-31 | CN¥211.61 Million ≈ $30.97 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Changzhou Qianhong Biopharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 741.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.04 Billion | 41.39% |
| Common Stock | CN¥1.28 Billion | 50.84% |
| Other Comprehensive Income | CN¥334.23 Million | 13.28% |
| Total Equity | CN¥2.52 Billion | 100.00% |
Changzhou Qianhong Biopharma Co Ltd Competitors by Market Cap
The table below lists competitors of Changzhou Qianhong Biopharma Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Afry AB
ST:AFRY
|
$1.31 Billion |
|
Grupo Aeroméxico S.A.B. de C.V
MX:AEROMEX
|
$1.31 Billion |
|
Sino Medical Sciences Technology In
SHG:688108
|
$1.31 Billion |
|
Jupiter Wagons Limited
NSE:JWL
|
$1.31 Billion |
|
Couchbase Inc
NASDAQ:BASE
|
$1.31 Billion |
|
Dogan Sirketler Grubu Holding AS
IS:DOHOL
|
$1.31 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
$1.31 Billion |
|
Labrador Iron Ore Royalty Corp
TO:LIF
|
$1.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Changzhou Qianhong Biopharma Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,454,931,005 to 2,517,442,607, a change of 62,511,602 (2.5%).
- Net income of 356,032,010 contributed positively to equity growth.
- Dividend payments of 151,521,781 reduced retained earnings.
- Share repurchases of 140,770,172 reduced equity.
- Other comprehensive income increased equity by 23,589,954.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥356.03 Million | +14.14% |
| Dividends Paid | CN¥151.52 Million | -6.02% |
| Share Repurchases | CN¥140.77 Million | -5.59% |
| Other Comprehensive Income | CN¥23.59 Million | +0.94% |
| Other Changes | CN¥-24.82 Million | -0.99% |
| Total Change | CN¥- | 2.55% |
Book Value vs Market Value Analysis
This analysis compares Changzhou Qianhong Biopharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 31.79x to 3.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.22 | CN¥7.00 | x |
| 2008-12-31 | CN¥0.23 | CN¥7.00 | x |
| 2009-12-31 | CN¥0.25 | CN¥7.00 | x |
| 2010-12-31 | CN¥0.41 | CN¥7.00 | x |
| 2011-12-31 | CN¥1.40 | CN¥7.00 | x |
| 2012-12-31 | CN¥1.43 | CN¥7.00 | x |
| 2013-12-31 | CN¥1.50 | CN¥7.00 | x |
| 2014-12-31 | CN¥1.63 | CN¥7.00 | x |
| 2015-12-31 | CN¥1.79 | CN¥7.00 | x |
| 2016-12-31 | CN¥1.93 | CN¥7.00 | x |
| 2017-12-31 | CN¥1.86 | CN¥7.00 | x |
| 2018-12-31 | CN¥1.94 | CN¥7.00 | x |
| 2019-12-31 | CN¥1.87 | CN¥7.00 | x |
| 2020-12-31 | CN¥1.67 | CN¥7.00 | x |
| 2021-12-31 | CN¥1.70 | CN¥7.00 | x |
| 2022-12-31 | CN¥1.91 | CN¥7.00 | x |
| 2023-12-31 | CN¥1.89 | CN¥7.00 | x |
| 2024-12-31 | CN¥1.98 | CN¥7.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Changzhou Qianhong Biopharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.14%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 23.33%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.12x
- Recent ROE (14.14%) is below the historical average (15.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 21.57% | 16.09% | 0.98x | 1.36x | CN¥24.47 Million |
| 2008 | 41.49% | 19.28% | 1.20x | 1.80x | CN¥68.64 Million |
| 2009 | 51.59% | 16.90% | 1.39x | 2.19x | CN¥101.33 Million |
| 2010 | 38.19% | 13.15% | 2.09x | 1.39x | CN¥111.11 Million |
| 2011 | 8.85% | 20.82% | 0.39x | 1.08x | CN¥-19.87 Million |
| 2012 | 8.86% | 22.21% | 0.38x | 1.05x | CN¥-20.90 Million |
| 2013 | 9.67% | 21.73% | 0.42x | 1.07x | CN¥-6.38 Million |
| 2014 | 11.67% | 30.08% | 0.35x | 1.10x | CN¥35.13 Million |
| 2015 | 11.75% | 35.29% | 0.27x | 1.25x | CN¥39.73 Million |
| 2016 | 9.35% | 28.91% | 0.26x | 1.26x | CN¥-15.60 Million |
| 2017 | 7.51% | 17.18% | 0.35x | 1.25x | CN¥-60.70 Million |
| 2018 | 8.75% | 16.75% | 0.42x | 1.26x | CN¥-31.63 Million |
| 2019 | 11.26% | 15.67% | 0.57x | 1.26x | CN¥29.37 Million |
| 2020 | -6.35% | -7.92% | 0.68x | 1.18x | CN¥-340.02 Million |
| 2021 | 8.51% | 9.66% | 0.75x | 1.18x | CN¥-31.65 Million |
| 2022 | 13.20% | 14.04% | 0.82x | 1.15x | CN¥78.38 Million |
| 2023 | 7.41% | 10.02% | 0.66x | 1.13x | CN¥-63.63 Million |
| 2024 | 14.14% | 23.33% | 0.54x | 1.12x | CN¥104.29 Million |
Industry Comparison
This section compares Changzhou Qianhong Biopharma Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Changzhou Qianhong Biopharma Co Ltd (002550) | CN¥2.76 Billion | 21.57% | 0.09x | $1.31 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more